Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Pooled Exposure-Response (ER) and Quantitative Benefit/Risk (B/R) Analyses Support the Approved Copanlisib Intermittent Dosing Regimen

Peter N Morcos, Jonathan Moss, Charles Phelps, Florian JR Hiemeyer, Barrett H. Childs, Martin Dreyling, Pier Luigi Zinzani, Dirk Garmann

Blood (2023) 142 (Supplement 1): 6156.

https://doi.org/10.1182/blood-2023-187153

Published: 2023

Journal Articles

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

Blood (2022) 140 (Supplement 1): 6470–6473.

https://doi.org/10.1182/blood-2022-167368

Published: 2022

Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Jonathan Moss, Dirk Garmann, Rupert Austin, Florian Hiemeyer, Matthew J. Matasar, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Peter N. Morcos

Blood (2022) 140 (Supplement 1): 3629–3631.

https://doi.org/10.1182/blood-2022-162819

Published: 2022

Journal Articles

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Barrett H Childs, Yuankai Shi, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2021-150873

Published: 2021

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD Prof, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Maria Dimou, MD PhD, Judit Demeter, MD PhD Dr. Sci, Massimo Magagnoli, MD, Liana Rodrigues, MD, Oliver Wirtz, MSc, Florian Hiemeyer, MSc, Li Liu, PhD, Karl Koechert, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 395.

https://doi.org/10.1182/blood-2018-99-116715

Published: 2018

Journal Articles

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2018-99-114842

Published: 2018

Journal Articles

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Pier Luigi Zinzani, MD, Armando Santoro, MD, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Liana Rodrigues, MD, John Reeves, PhD MS, Florian Hiemeyer, MSc, Ashok Miriyala, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2018-99-117063

Published: 2018

Journal Articles

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Martin Dreyling, MD PhD, Panayiotis Panayiotidis, MD PhD, Miklos Egyed, MD PhD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Luigina Mollica, MD PhD, Arnon Nagler, MD, Muhit Ozcan, MD, Armando Santoro, MD, Tatiane Ishida, MD, Cindy Lu, PhD, Florian Hiemeyer, MSc, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4053.

https://doi.org/10.1182/blood.V130.Suppl_1.4053.4053

Published: 2017

Journal Articles

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Pier Luigi Zinzani, MD PhD, Amita Patnaik, MD FRCP, Franck Morschhauser, MD PhD, Gilles Andre Salles, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Krimo Bouabdallah, MD, David Cunningham, MD FRCP, Sirpa Leppa, MD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Alice Benson, PhD, Peter Bonata, PhD, Isabelle Genvresse, MD, Ashok Miriyala, MD, Aruna Mehra, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin Dreyling, MD PhD

Blood (2017) 130 (Supplement 1): 4042.

https://doi.org/10.1182/blood.V130.Suppl_1.4042.4042

Published: 2017

Journal Articles

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Blood (2017) 130 (Supplement 1): 2777.

https://doi.org/10.1182/blood.V130.Suppl_1.2777.2777

Published: 2017

Journal Articles

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

David Cunningham, Pier Luigi Zinzani, MD PhD, Sarit E. Assouline, MDMSc, Krimo Bouabdallah, MD, Dominique Bron, MD PhD, Corinne Haioun, MD PhD, Luigina Mollica, MD FRCPC, PhD, Marius Giurescu, MDPhD, Igor Gorbatchevsky, MD, Manoel Neves, MD, Marta M. Lemos, MD, Julia Grunert, PhD, Florian Hiemeyer, PhD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 3935.

https://doi.org/10.1182/blood.V126.23.3935.3935

Published: 2015

Journal Articles

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

Martin Dreyling, David Cunningham, FMedSci, Krimo Bouabdallah, MD, Sarit Assouline, MD MSc, Eric Van den Neste, Umberto Vitolo, MD, Marius Giurescu, MD PhD, Silvia Mappa, MD, Julia Grunert, Barrett H. Childs, MD, Franck Morschhauser

Blood (2014) 124 (21): 1701.

https://doi.org/10.1182/blood.V124.21.1701.1701

Published: 2014

Journal Articles

Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma

Martin Dreyling, Franck Morschhauser, MD, PhD, Dominique Bron, MD, PhD, Krimo Bouabdallah, MD, Umberto Vitolo, MD, Kim Linton, Eric Van Den Neste, MD, PhD, Silvia Mappa, MD, Marius Giurescu, MD, PhD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD

Blood (2013) 122 (21): 87.

https://doi.org/10.1182/blood.V122.21.87.87

Published: 2013

Journal Articles

T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease

Esperanza B. Papadopoulos, Matthew H. Carabasi, Hugo Castro-Malaspina, Barrett H. Childs, Stephen Mackinnon, Farid Boulad, Alfred P. Gillio, Nancy A. Kernan, Trudy N. Small, Paul Szabolcs, Joanne Taylor, Joachim Yahalom, Nancy H. Collins, Sharon A. Bleau, Patricia M. Black, Glenn Heller, Richard J. O' Reilly, James W. Young

Blood (1998) 91 (3): 1083–1090.

https://doi.org/10.1182/blood.V91.3.1083

Published: 1998

NARROW

Pooled Exposure-Response (ER) and Quantitative Benefit/Risk (B/R) Analyses Support the Approved Copanlisib Intermittent Dosing Regimen

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma

T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only